This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kenerson, H. L. Articles by Yeung, R. S. Search for Related Content PubMed PubMed Citation Articles by Kenerson, H. L. Articles by Yeung, R. S.

Activated Mammalian Target of Rapamycin Pathway in the Pathogenesis of Tuberous Sclerosis Complex Renal Tumors¹

Departments of Surgery [H. L. K., L. D. A., R. S. Y.] and Pathology [L. D. T.], University of Washington, Seattle, Washington 98195

Disruption of the TSC1 or TSC2 gene leads to the development of tumors in multiple organs, most commonly affecting the kidney, brain, lung, and heart. Recent genetic and biochemical studies have identified a role for the tuberous sclerosis gene products in phosphoinositide 3-kinase signaling. On growth factor stimulation, tuberin, the TSC2 protein, is phosphorylated by Akt, thereby releasing its inhibitory effects on p70S6K. Here we demonstrate that primary tumors from tuberous sclerosis complex (TSC) patients and the Eker rat model of TSC expressed elevated levels of phosphorylated mammalian target of rapamycin (mTOR) and its effectors: p70S6K, S6 ribosomal protein, 4E-BP1, and eIF4G. In the Eker rat, short-term inhibition of mTOR by rapamycin was associated with a significant tumor response, including induction of apoptosis and reduction in cell proliferation. Surprisingly, these changes were not accompanied by significant alteration in cyclin D1 and p27 levels. Our data provide in vivo evidence that the mTOR pathway is aberrantly activated in TSC renal pathology and that treatment with rapamycin appears effective in the preclinical setting.

This article has been cited by other articles:

				J. J. Bissler, F. X. McCormack, L. R. Young, J. M. Elwing, G. Chuck, J. M. Leonard, V. J. Schmithorst, T. Laor, A. S. Brody, J. Bean, et al. Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis N. Engl. J. Med., January 10, 2008; 358(2): 140 - 151. [Abstract] [Full Text] [PDF]

				E. Paul and E. Thiele Efficacy of Sirolimus in Treating Tuberous Sclerosis and Lymphangioleiomyomatosis N. Engl. J. Med., January 10, 2008; 358(2): 190 - 192. [Full Text] [PDF]

				L. J. Costa and H. A. Drabkin Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies Oncologist, December 1, 2007; 12(12): 1404 - 1415. [Abstract] [Full Text] [PDF]

				G. P Cosgrove, S. K Frankel, and K. K Brown Challenges in pulmonary fibrosis {middle dot} 3: Cystic lung disease Thorax, September 1, 2007; 62(9): 820 - 829. [Abstract] [Full Text] [PDF]

				N. J. Laping, J. I. Everitt, K. S. Frazier, M. Burgert, M. J. Portis, C. Cadacio, L. I. Gold, and C. L. Walker Tumor-Specific Efficacy of Transforming Growth Factor-{beta}RI Inhibition in Eker Rats Clin. Cancer Res., May 15, 2007; 13(10): 3087 - 3099. [Abstract] [Full Text] [PDF]

				S. C. Juvet, F. X. McCormack, D. J. Kwiatkowski, and G. P. Downey Molecular Pathogenesis of Lymphangioleiomyomatosis: Lessons Learned from Orphans Am. J. Respir. Cell Mol. Biol., April 1, 2007; 36(4): 398 - 408. [Abstract] [Full Text] [PDF]

				D. C. Birle and D. W. Hedley Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts. Mol. Cancer Ther., October 1, 2006; 5(10): 2494 - 2502. [Abstract] [Full Text] [PDF]

				O. J. Shah and T. Hunter Turnover of the Active Fraction of IRS1 Involves Raptor-mTOR- and S6K1-Dependent Serine Phosphorylation in Cell Culture Models of Tuberous Sclerosis. Mol. Cell. Biol., September 1, 2006; 26(17): 6425 - 6434. [Abstract] [Full Text] [PDF]

				S. R. Johnson Lymphangioleiomyomatosis. Eur. Respir. J., May 1, 2006; 27(5): 1056 - 1065. [Abstract] [Full Text] [PDF]

				J. M. Shillingford, N. S. Murcia, C. H. Larson, S. H. Low, R. Hedgepeth, N. Brown, C. A. Flask, A. C. Novick, D. A. Goldfarb, A. Kramer-Zucker, et al. From the Cover: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease PNAS, April 4, 2006; 103(14): 5466 - 5471. [Abstract] [Full Text] [PDF]

				T. M. Kolb, L. Duan, and M. A. Davis Tsc2 Expression Increases the Susceptibility of Renal Tumor Cells to Apoptosis Toxicol. Sci., December 1, 2005; 88(2): 331 - 339. [Abstract] [Full Text] [PDF]

				M. KARBOWNICZEK and E. P. HENSKE The Role of Tuberin in Cellular Differentiation: Are B-Raf and MAPK Involved? Ann. N.Y. Acad. Sci., November 1, 2005; 1059(1): 168 - 173. [Abstract] [Full Text] [PDF]

				E. Lesma, V. Grande, S. Carelli, D. Brancaccio, M. P. Canevini, R. M. Alfano, G. Coggi, A. M. Di Giulio, and A. Gorio Isolation and Growth of Smooth Muscle-Like Cells Derived from Tuberous Sclerosis Complex-2 Human Renal Angiomyolipoma: Epidermal Growth Factor Is the Required Growth Factor Am. J. Pathol., October 1, 2005; 167(4): 1093 - 1103. [Abstract] [Full Text] [PDF]

				N. El-Hashemite and D. J. Kwiatkowski Interferon-{gamma}-Jak-Stat Signaling in Pulmonary Lymphangioleiomyomatosis and Renal Angiomyolipoma: A Potential Therapeutic Target Am. J. Respir. Cell Mol. Biol., September 1, 2005; 33(3): 227 - 230. [Abstract] [Full Text] [PDF]

				B. D. Manning, M. N. Logsdon, A. I. Lipovsky, D. Abbott, D. J. Kwiatkowski, and L. C. Cantley Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2 Genes & Dev., August 1, 2005; 19(15): 1773 - 1778. [Abstract] [Full Text] [PDF]

				B. C. Mak, H. L. Kenerson, L. D. Aicher, E. A. Barnes, and R. S. Yeung Aberrant {beta}-Catenin Signaling in Tuberous Sclerosis Am. J. Pathol., July 1, 2005; 167(1): 107 - 116. [Abstract] [Full Text] [PDF]

				C.-L. Gau, J. Kato-Stankiewicz, C. Jiang, S. Miyamoto, L. Guo, and F. Tamanoi Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways Mol. Cancer Ther., June 1, 2005; 4(6): 918 - 926. [Abstract] [Full Text] [PDF]

				H. Takeuchi, Y. Kondo, K. Fujiwara, T. Kanzawa, H. Aoki, G. B. Mills, and S. Kondo Synergistic Augmentation of Rapamycin-Induced Autophagy in Malignant Glioma Cells by Phosphatidylinositol 3-Kinase/Protein Kinase B Inhibitors Cancer Res., April 15, 2005; 65(8): 3336 - 3346. [Abstract] [Full Text] [PDF]

				K. Inoki, H. Ouyang, Y. Li, and K.-L. Guan Signaling by Target of Rapamycin Proteins in Cell Growth Control Microbiol. Mol. Biol. Rev., March 1, 2005; 69(1): 79 - 100. [Abstract] [Full Text] [PDF]

				J. Dong, J. Peng, H. Zhang, W. H. Mondesire, W. Jian, G. B. Mills, M.-C. Hung, and F. Meric-Bernstam Role of Glycogen Synthase Kinase 3{beta} in Rapamycin-Mediated Cell Cycle Regulation and Chemosensitivity Cancer Res., March 1, 2005; 65(5): 1961 - 1972. [Abstract] [Full Text] [PDF]

				T. Chiu, C. Santiskulvong, and E. Rozengurt EGF receptor transactivation mediates ANG II-stimulated mitogenesis in intestinal epithelial cells through the PI3-kinase/Akt/mTOR/p70S6K1 signaling pathway Am J Physiol Gastrointest Liver Physiol, February 1, 2005; 288(2): G182 - G194. [Abstract] [Full Text] [PDF]

				B. D. Manning Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis J. Cell Biol., November 8, 2004; 167(3): 399 - 403. [Abstract] [Full Text] [PDF]

				M. M. Fraser, X. Zhu, C.-H. Kwon, E. J. Uhlmann, D. H. Gutmann, and S. J. Baker Pten Loss Causes Hypertrophy and Increased Proliferation of Astrocytes In vivo Cancer Res., November 1, 2004; 64(21): 7773 - 7779. [Abstract] [Full Text] [PDF]

				Y. Li, K. Inoki, and K.-L. Guan Biochemical and Functional Characterizations of Small GTPase Rheb and TSC2 GAP Activity Mol. Cell. Biol., September 15, 2004; 24(18): 7965 - 7975. [Abstract] [Full Text] [PDF]

				K.-S. Au, A. T. Williams, M. J. Gambello, and H. Northrup Molecular Genetic Basis of Tuberous Sclerosis Complex: From Bench to Bedside J Child Neurol, September 1, 2004; 19(9): 699 - 709. [Abstract] [PDF]

				A. Astrinidis and E. Petri Henske Aberrant Cellular Differentiation and Migration in Renal and Pulmonary Tuberous Sclerosis Complex J Child Neurol, September 1, 2004; 19(9): 710 - 715. [Abstract] [PDF]

				P. B. Crino Molecular Pathogenesis of Tuber Formation in Tuberous Sclerosis Complex J Child Neurol, September 1, 2004; 19(9): 716 - 725. [Abstract] [PDF]

				T. M. Kolb and M. A. Davis The Tumor Promoter 12-O-Tetradecanoylphorbol 13-acetate (TPA) Provokes a Prolonged Morphologic Response and ERK Activation in Tsc2-Null Renal Tumor Cells Toxicol. Sci., September 1, 2004; 81(1): 233 - 242. [Abstract] [Full Text] [PDF]

				L. S. Harrington, G. M. Findlay, A. Gray, T. Tolkacheva, S. Wigfield, H. Rebholz, J. Barnett, N. R. Leslie, S. Cheng, P. R. Shepherd, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins J. Cell Biol., July 19, 2004; 166(2): 213 - 223. [Abstract] [Full Text] [PDF]

				M. Karbowniczek, T. Cash, M. Cheung, G. P. Robertson, A. Astrinidis, and E. P. Henske Regulation of B-Raf Kinase Activity by Tuberin and Rheb Is Mammalian Target of Rapamycin (mTOR)-independent J. Biol. Chem., July 16, 2004; 279(29): 29930 - 29937. [Abstract] [Full Text] [PDF]

				M. N. Corradetti, K. Inoki, N. Bardeesy, R. A. DePinho, and K.-L. Guan Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome Genes & Dev., July 1, 2004; 18(13): 1533 - 1538. [Abstract] [Full Text] [PDF]

				N. El-Hashemite, H. Zhang, V. Walker, K. M. Hoffmeister, and D. J. Kwiatkowski Perturbed IFN-{gamma}-Jak-Signal Transducers and Activators of Transcription Signaling in Tuberous Sclerosis Mouse Models: Synergistic Effects of Rapamycin-IFN-{gamma} Treatment Cancer Res., May 15, 2004; 64(10): 3436 - 3443. [Abstract] [Full Text] [PDF]

				J. Yu, A. Astrinidis, S. Howard, and E. P. Henske Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways Am J Physiol Lung Cell Mol Physiol, April 1, 2004; 286(4): L694 - L700. [Abstract] [Full Text] [PDF]

				S. Han, T. M. Santos, A. Puga, J. Roy, E. A. Thiele, M. McCollin, A. Stemmer-Rachamimov, and V. Ramesh Phosphorylation of Tuberin as a Novel Mechanism for Somatic Inactivation of the Tuberous Sclerosis Complex Proteins in Brain Lesions Cancer Res., February 1, 2004; 64(3): 812 - 816. [Abstract] [Full Text] [PDF]

				V. Murthy, S. Han, R. L. Beauchamp, N. Smith, L. A. Haddad, N. Ito, and V. Ramesh Pam and Its Ortholog Highwire Interact with and May Negatively Regulate the TSC1{middle dot}TSC2 Complex J. Biol. Chem., January 9, 2004; 279(2): 1351 - 1358. [Abstract] [Full Text] [PDF]

				A. Astrinidis, W. Senapedis, T. R. Coleman, and E. P. Henske Cell Cycle-regulated Phosphorylation of Hamartin, the Product of the Tuberous Sclerosis Complex 1 Gene, by Cyclin-dependent Kinase 1/Cyclin B J. Biol. Chem., December 19, 2003; 278(51): 51372 - 51379. [Abstract] [Full Text] [PDF]

				N. El-Hashemite, V. Walker, H. Zhang, and D. J. Kwiatkowski Loss of Tsc1 or Tsc2 Induces Vascular Endothelial Growth Factor Production through Mammalian Target of Rapamycin Cancer Res., September 1, 2003; 63(17): 5173 - 5177. [Abstract] [Full Text] [PDF]

				K. Inoki, Y. Li, T. Xu, and K.-L. Guan Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling Genes & Dev., August 1, 2003; 17(15): 1829 - 1834. [Abstract] [Full Text] [PDF]

				B. C. Mak, K.-I. Takemaru, H. L. Kenerson, R. T. Moon, and R. S. Yeung The Tuberin-Hamartin Complex Negatively Regulates beta -Catenin Signaling Activity J. Biol. Chem., February 14, 2003; 278(8): 5947 - 5951. [Abstract] [Full Text] [PDF]